|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data suggest that the p73 gene is not playing an essential role, but expression of p73 may associate with tumor growth in prostatic carcinogenesis.
|
9605745 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The presence of methylation of these genes or a group of genes was not associated with any distinct clinicopathological characteristics including tumor grade, proliferation activity, responsiveness to adjuvant therapy, or patient survival. p73 protein accumulation was demonstrated by immunohistochemical staining in 6 (15%) of the 40 samples examined, with no significant association with the methylation status of p73 and any of the clinicopathological parameters tested.
|
17016577 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of p73 is low in uncultured basal keratinocytes but is markedly up-regulated in both SCC cell lines and primary tumors in vivo.
|
17018588 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, Mdm2 overexpression and p73 loss cooperate in genomic instability and tumor development, indicating that the oncogenic function of Mdm2 is a combined effect of inhibiting p53 and p73 functions.
|
25915849 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ectopic p73 overexpression largely mimics p53 activities as a tumor suppressor and activates the transcription of p53-responsive genes and as a result induce apoptosis.
|
31850263 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In 87% of the cases (52/60) p73 expression in tumour was more than twice as high as that in paired normal lung tissues, and the difference between p73 expression in tumour and normal lung tissue was significant (P < 0.0001).
|
10408409 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Informative cases were examined for p73 LOH within the tumour.
|
11720435 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared p53 and p73 interactions with HBx in normal and HCC tumor cell lines differing in their p53 status.
|
22030623 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The recent finding that the 1p36.3 locus gene encodes an array of different p73 isoforms with apparently distinct and sometimes opposing cellular functions, might explain the difficulty in establishing the protein's role as tumor suppressor.
|
16721041 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inactivation of the product of the tumor suppressor gene TP73 does not usually occur by mutation but rather through expression of truncated isoforms that have dominant-negative effects on p73 and p53.
|
19664633 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoplasmic pro-apoptotic function of the tumor suppressor p73 is mediated through a modified mode of recognition of the anti-apoptotic regulator Bcl-X<sub>L</sub>.
|
30429221 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated for the first time the genetic and expression status of the p73 gene and analyzed its flanking microsatellite loci on chromosome 1p36.3 in 67 primary oral and laryngeal squamous cell carcinomas to determine their association with these tumors.
|
11323391 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine whether p73 is involved in nonastrocytic brain tumour development, we analysed 65 tumour samples including 26 oligodendrogliomas, 4 ependymomas, 5 medulloblastomas, 10 meningiomas, 2 meningeal haemangiopericytomas, 2 neurofibrosarcomas, 3 primary lymphomas, 8 schwannomas and 5 metastatic tumours to the brain, for p73 alterations.
|
11461077 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of p73 in the peripheral blood of children with WT was positively correlated with the clinical stage of the tumor, and was closely related with the low survival rate of patients.
|
31186762 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The cause or consequence of overexpression of p73 (refs 1, 2), the structural and functional homologue of the tumour-suppressor gene product p53 (refs 3, 4), in human cancers is poorly understood.
|
17496887 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, several candidate tumor suppressor genes such as p16INK4a, p15INK4b, and p73 that were previously reported as unmutated in oligodendroglial tumors were found to be hypermethylated in their CpG islands.
|
11487055 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of p73 in tumor development is still unclear and no data on ovarian cancer are so far available.
|
10509157 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Isoform-specific real-time reverse transcription-polymerase chain reaction was used for the analysis of Tp73 isoform transcript expression in a series of 51 adult patients harbouring glial tumours, in order to compare tumour grades with each other, and with non-tumoural samples obtained from epileptic patients as well.
|
17047653 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, analysis of the tumor suppressor genes, p16(INK4a), p73 and PTEN located in 9p21, 1p36 and 10q23, respectively, revealed the participation of p16(INK4a) and p73 but not of PTEN.
|
12681362 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, after excluding one study deviating from Hardy-Weinberg equilibrium, the results then demonstrated that the p73 G4C14-A4T14 polymorphism was only associated with elevated risk of cervical squamous cell carcinoma (for AT/GC vs GC/GC: OR 1.51, 95 % CI 1.14-2.00, P heterogeneity = 0.996; for AT/AT+AT/GC vs GC/GC: OR 1.42, 95 % CI 1.08-1.87, P heterogeneity = 0.994) in subgroup analysis by tumor sites.
|
25516466 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall the data suggest that p73 may play an important role in the pathogenesis of neuroblastoma but that the true tumor suppressor gene localized to this area still remains to be identified.
|
10601564 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction between p53 mutants and p63 or p73 was confirmed in a physiological setting by examining tumor cell lines that endogenously express these proteins.
|
11238924 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative PCR demonstrated that p73 expression is the same in both normal and tumor prostate tissues.
|
10221564 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that, in CRCs, p73 may not play a role as a tumor suppressor, at least not in a classic Knudson manner.
|
9664127 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An unconditional logistic regression model demonstrated a significant association between the p73 AA genotype and an increased risk of endometrial cancer (OR=2.82, 95% CI=1.36-5.82), especially of type-I tumors (OR=3.24, 95% CI=1.53-6.87).
|
15723718 |
2005 |